Divarasib: Great Timing for Positive Data Makes This KRAS Inhibitor a Big Deal
divarasib
oral selective covalent KRASG12C inhibitor Ph. III for NSCLC from disulfide-tether fragment screen N. Engl. J. Med., August 2023 Genentech, So. San Francisco, CA
Loading...
